NVCR
BEARISH
$12.17
Live
NovoCure Limited · NASDAQ
Target $25.07
(+106.0%)
$9.82
52W Range
$20.06
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$1.38B
P/E
N/A
ROE
-38.9%
Profit margin
-20.8%
Debt/Equity
0.73
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.
Key Strengths
High Gross Margin (74.80%) indicating strong product value
Strong short-term liquidity with a Current Ratio of 2.90
Improving EPS growth YoY (+63.9%) despite remaining negative
Consistent earnings beats in 3 of the last 4 quarters
Manageable Debt/Equity ratio of 0.73
Key Risks
Weak financial health as indicated by Piotroski F-Score (3/9)
Severe long-term value destruction (-93.7% 5-year return)
Negative operating and profit margins (-21.33% and -20.79%)
Strong insider selling pressure with zero buy transactions in 6 months
Low revenue growth (8.10%) relative to the risk profile of a medical device firm
AI Fair Value Estimate
Based on comprehensive analysis
$11.5
-5.5% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
30
45
10
35
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score, Insider Selling, Long-term Price Trend, Negative Profitability
Confidence
90%
Value
30/100
Valuation is speculative as the company is not yet profitable.
Positives
- Reasonable Price/Sales ratio (2.11)
Watchpoints
- Negative P/E
- High Price/Book (4.02) for a loss-making entity
- No Graham Number available
Future
45/100
Growth is present but insufficient to offset current burn rates.
Positives
- Improving EPS trajectory
- High analyst price targets
Watchpoints
- Modest revenue growth (8.1%)
- Persistent operating losses
Past
10/100
Historical performance is extremely poor.
Positives
- Recent 1-week bounce (+12.8%)
Watchpoints
- 5-year return of -93.7%
- Consistent downward trend over 1, 3, and 5 year horizons
Health
35/100
Liquidity is high, but operational health is poor.
Positives
- Strong Current and Quick ratios
- Low Debt/Equity compared to sector average
Watchpoints
- Piotroski F-Score of 3/9 (Weak)
- Negative ROE (-38.89%)
Dividend
0/100
Non-dividend paying growth/speculative stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$12.17
Analyst Target
$25.07
Upside/Downside
+106.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NVCR and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NVCR
NovoCure Limited
Primary
|
-93.7% | -81.1% | -26.1% | -14.2% | -1.7% | +12.8% |
|
HCSG
Healthcare Services Group, Inc.
Peer
|
-26.4% | +29.9% | +99.3% | +28.4% | -2.7% | +6.2% |
|
PGEN
Precigen, Inc.
Peer
|
-46.5% | +240.5% | +188.3% | +13.2% | +11.6% | -7.5% |
|
IMTX
Immatics N.V.
Peer
|
-10.0% | +69.3% | +162.7% | +0.7% | +4.0% | +0.8% |
|
NVAX
Novavax, Inc.
Peer
|
-96.2% | -8.1% | +36.0% | -2.5% | -13.8% | +3.2% |
NVC
NovoCure Limited
Primary
5Y
-93.7%
3Y
-81.1%
1Y
-26.1%
6M
-14.2%
1M
-1.7%
1W
+12.8%
HCS
Healthcare Services Group, Inc.
Peer
5Y
-26.4%
3Y
+29.9%
1Y
+99.3%
6M
+28.4%
1M
-2.7%
1W
+6.2%
PGE
Precigen, Inc.
Peer
5Y
-46.5%
3Y
+240.5%
1Y
+188.3%
6M
+13.2%
1M
+11.6%
1W
-7.5%
IMT
Immatics N.V.
Peer
5Y
-10.0%
3Y
+69.3%
1Y
+162.7%
6M
+0.7%
1M
+4.0%
1W
+0.8%
NVA
Novavax, Inc.
Peer
5Y
-96.2%
3Y
-8.1%
1Y
+36.0%
6M
-2.5%
1M
-13.8%
1W
+3.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-10.44
PEG Ratio
N/A
P/B Ratio
4.02
P/S Ratio
2.11
EV/Revenue
1.81
EV/EBITDA
-8.77
Market Cap
$1.38B
Profitability
Profit margins and return metrics
Profit Margin
-20.79%
Operating Margin
-21.33%
Gross Margin
74.8%
ROE
-38.89%
ROA
-9.06%
Growth
Revenue and earnings growth rates
Revenue Growth
+8.1%
Earnings Growth
N/A
Q/Q Revenue Growth
+8.11%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.73
Moderate
Current Ratio
2.9
Strong
Quick Ratio
2.51
Excellent
Cash/Share
$3.93
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
75.8%
Op. Margin
-23.2%
Net Margin
-14.1%
Total Assets
$0.8B
Liabilities
$0.5B
Equity
$0.3B
Debt/Equity
1.36x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
127%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-26
$-0.22
+46.5% surprise
2025-10-30
$-0.33
+21.4% surprise
2025-07-24
$-0.36
+7.3% surprise
Healthcare Sector Comparison
Comparing NVCR against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-38.89%
This Stock
vs
-100.15%
Sector Avg
-61.2%
(Below Avg)
Profit Margin
-20.79%
This Stock
vs
-13.63%
Sector Avg
+52.5%
(Superior)
Debt to Equity
0.73
This Stock
vs
3.22
Sector Avg
-77.3%
(Less Debt)
Revenue Growth
8.1%
This Stock
vs
121.05%
Sector Avg
-93.3%
(Slower)
Current Ratio
2.9
This Stock
vs
4.55
Sector Avg
-36.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NVCR
NovoCure Limited
|
BEARISH | $1.38B | - | -38.9% | -20.8% | $12.17 | |
|
HCSG
Healthcare Services Group, Inc.
|
BULLISH | $1.37B | 24.06 | 11.7% | 3.2% | $19.49 | Compare |
|
PGEN
Precigen, Inc.
|
BEARISH | $1.4B | - | -572.0% | -% | $3.95 | Compare |
|
IMTX
Immatics N.V.
|
BEARISH | $1.4B | - | -37.1% | -% | $10.43 | Compare |
|
NVAX
Novavax, Inc.
|
NEUTRAL | $1.42B | 3.25 | -% | 39.2% | $8.69 | Compare |
NVCR
NovoCure Limited
BEARISH
Mkt Cap
$1.4B
P/E
-
ROE
-38.9%
Price
$12.17
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | PARAVASTHU MUKUND | Chief Operating Officer | Sale | 48,623 | $667,214 |
| 2026-03-04 | PURI MICHAL NATH | Officer | Sale | 1,100 | $14,636 |
| 2026-03-04 | LEUPIN NICOLAS | Former | Sale | 1,100 | $14,636 |
| 2026-03-04 | BRACKMANN CHRISTOPH | Chief Financial Officer | Sale | 6,412 | $85,314 |
| 2026-03-04 | WEINBERG URI | Officer | Sale | 6,412 | $85,314 |
| 2026-03-04 | LEONARD FRANCIS XAVIER II | Chief Executive Officer | Sale | 5,607 | $74,603 |
| 2026-03-03 | DOYLE WILLIAM F | Officer and Director | Stock Award | 400,284 | - |
| 2026-03-03 | DOYLE WILLIAM F | Officer and Director | Sale | 71,887 | $932,883 |
| 2026-03-03 | PURI MICHAL NATH | Officer | Stock Award | 40,100 | - |
| 2026-03-03 | PARAVASTHU MUKUND | Chief Operating Officer | Stock Award | 45,112 | - |
| 2026-03-03 | BRACKMANN CHRISTOPH | Chief Financial Officer | Stock Award | 55,137 | - |
| 2026-03-03 | WEINBERG URI | Officer | Stock Award | 50,125 | - |
| 2026-03-03 | LEONARD FRANCIS XAVIER II | Chief Executive Officer | Stock Award | 150,000 | - |
| 2026-03-03 | BEN ARYE BARAK | General Counsel | Stock Award | 50,125 | - |
| 2026-03-02 | PARAVASTHU MUKUND | Chief Operating Officer | Sale | 1,963 | $26,752 |
PARAVASTHU MUKUND
Chief Operating Officer
2026-03-05
48,623 shares
·
$667,214
PURI MICHAL NATH
Officer
2026-03-04
1,100 shares
·
$14,636
LEUPIN NICOLAS
Former
2026-03-04
1,100 shares
·
$14,636
BRACKMANN CHRISTOPH
Chief Financial Officer
2026-03-04
6,412 shares
·
$85,314
WEINBERG URI
Officer
2026-03-04
6,412 shares
·
$85,314
LEONARD FRANCIS XAVIER II
Chief Executive Officer
2026-03-04
5,607 shares
·
$74,603
DOYLE WILLIAM F
Officer and Director
2026-03-03
400,284 shares
DOYLE WILLIAM F
Officer and Director
2026-03-03
71,887 shares
·
$932,883
PURI MICHAL NATH
Officer
2026-03-03
40,100 shares
PARAVASTHU MUKUND
Chief Operating Officer
2026-03-03
45,112 shares
BRACKMANN CHRISTOPH
Chief Financial Officer
2026-03-03
55,137 shares
WEINBERG URI
Officer
2026-03-03
50,125 shares
LEONARD FRANCIS XAVIER II
Chief Executive Officer
2026-03-03
150,000 shares
BEN ARYE BARAK
General Counsel
2026-03-03
50,125 shares
PARAVASTHU MUKUND
Chief Operating Officer
2026-03-02
1,963 shares
·
$26,752
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
7 analysts
HC Wainwright & Co.
2026-02-26
Buy
Buy
HC Wainwright & Co.
2026-02-12
Buy
Buy
Wedbush
2026-01-15
Neutral
Neutral
HC Wainwright & Co.
2026-01-13
Buy
Buy
HC Wainwright & Co.
2025-10-30
Buy
Buy
JP Morgan
2025-10-27
Neutral
Neutral
Past News Coverage
Recent headlines mentioning NVCR from our newsroom.
Newest → oldest
No matching news yet.